Targeting Novartis' Scemblix, Enliven lays out case for leukemia drug in early results

Max Gelman

Senior Editor

Enliven Therapeutics released new Phase 1 data for its chronic myeloid leukemia program (CML) it hopes can eventually compete with Novartis’ Scemblix.

The experimental therapy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Targeting Novartis' Scemblix, Enliven lays out case for leukemia drug in early results

Max Gelman

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Ron Renaud's new obesity biotech, Kailera, has $400M to go straight to Phase 3

Metsera partners with Amneal to manufacture obesity drugs, and Clive Meanwell hands over CEO role

IGM scraps oncology work to focus on autoimmune, loses three executives

CAMP4, preparing for IPO, announces partnership with BioMarin

Shattuck Labs cuts CD47 program and 40% of workforce as it focuses on IBD drug

3 Tiers for AAV Potency Assay Development Success

Tar­get­ing No­var­tis' Scem­blix, En­liv­en lays out case for leukemia drug in ear­ly re­sults

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Targeting Novartis' Scemblix, Enliven lays out case for leukemia drug in early results